banner

Cellceutix Files IND; Cancer Trials to be Held at Dana-Farber

Cellceutix Corporation (CTIX)

Cellceutix Corporation (OTCBB:CTIX) has filed its Investigational New Drug (IND) application for Kevetrin™, a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating the clinical trial. During this time, the FDA reviews the data in the IND and determines the conditions under which human trials can commence.


The Phase I trial is planned to take place at Dana-Farber Cancer Institute and its partner hospitals including Beth Israel Deaconess Medical Center.  The clinical trial will test Kevetrin™ against a variety of different cancer types in patients with advanced-stage cancers.  Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.

Cellceutix is focused on developing Kevetrin™ as a new class of chemotherapy for treatment of solid tumors.   Mechanism of action studies showed Kevetrin’s unique ability to affect both wild and mutant types of p53, and that Kevetrin strongly induced apoptosis, characterized by activation of Caspase 3 and cleavage of PARP.  Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis,  or cellular senescence. It is often referred to as the “Guardian Angel of the Human Genome.

Cellceutix CEO Leo Ehrlich stated,

The filing of the IND represents a historic day for Cellceutix and its shareholders.  We cannot possibly express how pleased we are to be making the shift to a clinical stage company.

About Dana-Farber/Harvard Cancer Center

More information on Dana-Farber/Harvard Cancer Center can be found at http://www.dfhcc.harvard.edu/

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix’s success are more fully disclosed in Cellceutix’s most recent public filings with the U.S. Securities and Exchange Commission.

Contact:
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
[email protected]

Cellceutix (CTIX) Stock Quote and News:







Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials(0)

Sunshine Biopharma Inc. (OTCQB: SBFM) reported on Thursday that it is in negotiations with Contract Manufacturing Organizations, or CMOs, as the next progression towards the anticipated clinical trials of its flagship cancer drug, Adva-27a, against multi-drug resistant forms of breast cancer. The trials are scheduled to be hosted by the leading cancer center Jewish General

Just Watch:  Online Gambling Today, Augmented Reality Online Gambling Tomorrow

Just Watch: Online Gambling Today, Augmented Reality Online Gambling Tomorrow(0)

The online gambling business is a hotbed of activity lately with Nevada, Delaware and New Jersey passing legislation permitting Internet betting with real money.  Bills have already been introduced in several other states as well, including California, Iowa and Mississippi, to legalize online wagering. There’s good reason for the markets buzzing about the potential revenues

ALR Technologies Partners with Mid-America Coalition in Bid to Commercialize Diabetes Management Program

ALR Technologies Partners with Mid-America Coalition in Bid to Commercialize Diabetes Management Program(0)

ALR Technologies Inc. (OTCBB: ALRT) took a big step in the direction of commercializing their Health-e-Connect Diabetes Management Program with news this week that the company has partnered with the Mid-America Coalition on Health Care, or MACHC.  The new pact means that MACHC will be introducing the ALRT program for pilot participation by its membership,

Face Up Entertainment Teams with Bad Beat on Hunger

Face Up Entertainment Teams with Bad Beat on Hunger(0)

Reality gaming social network company Face Up Entertainment Group, Inc. (OTCBB: FUEG) said late Wednesday that it has partnered with Bad Beat on Hunger, Inc. in the battle against childhood hunger in the U.S.  Bad Beat on Hunger is a venture between ForeverGreen International (OTCBB: FVRG) and the Happy Children Foundation helping to put food

Tactical Air Defense Services Buying Air 1 Flight Support

Tactical Air Defense Services Buying Air 1 Flight Support(0)

Tactical Air Defense Services, Inc. (Pinksheets: TADF) said Friday morning that it has signed a Letter of Intent to acquire 100 percent of Air 1 Flight Support, Inc. a privately-held provider of aircraft maintenance, refueling and support services headquartered in Denison, Texas, in an all-stock transaction. Tactical Air Defense Services is certified by the U.S.

read more
banner


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.